Jason Hannon is CEO of Mainstay Medical, the company that developed the ReActiv8 system to treat disabling chronic low back pain. ReActiv8 treats multifidus muscle dysfunction, a major underlying driver of back pain. The system has been extensively studied, both clinically and via basic science, and is commercially available in the United States, the U.K., Germany, and Australia. Prior to Mainstay, Jason served in executive leadership roles at NuVasive Inc., including as President/COO as well as head of International and corporate development.
Disclosure information not submitted.
Perspective from Tier 1 Operators in Business
Friday, May 1, 2026
11:10 AM - 11:59 AM CT